These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 31365755

  • 1. Overview: FDA Approval of Olaparib Maintenance for BRCA-Mutated.
    Saleh N, Copur MS.
    Oncology (Williston Park); 2019 Jul 15; 33(7):. PubMed ID: 31365755
    [No Abstract] [Full Text] [Related]

  • 2. It's About Time!
    Tempero M.
    J Natl Compr Canc Netw; 2020 Feb 15; 18(2):115. PubMed ID: 32023523
    [No Abstract] [Full Text] [Related]

  • 3. Olaparib, a new hope for ovarian cancer.
    Samoon Z, Jabbar AA.
    Indian J Cancer; 2020 Feb 15; 57(3):346-347. PubMed ID: 32675438
    [No Abstract] [Full Text] [Related]

  • 4. What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment?
    Liu JF, Matulonis UA.
    Curr Oncol Rep; 2016 May 15; 18(5):29. PubMed ID: 26984416
    [Abstract] [Full Text] [Related]

  • 5. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
    Rafii S, Gourley C, Kumar R, Geuna E, Ern Ang J, Rye T, Chen LM, Shapira-Frommer R, Friedlander M, Matulonis U, De Greve J, Oza AM, Banerjee S, Molife LR, Gore ME, Kaye SB, Yap TA.
    Oncotarget; 2017 Jul 18; 8(29):47154-47160. PubMed ID: 28454085
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial.
    DiSilvestro P, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian CA, Bradley WH, Mathews CA, Liu J, Lowe ES, Bloomfield R, Moore KN.
    J Clin Oncol; 2020 Oct 20; 38(30):3528-3537. PubMed ID: 32749942
    [Abstract] [Full Text] [Related]

  • 7. Olaparib (Lynparza) for advanced ovarian cancer.
    Med Lett Drugs Ther; 2016 Feb 29; 58(1489):e32-3. PubMed ID: 26938702
    [No Abstract] [Full Text] [Related]

  • 8. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.
    Ledermann JA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Spencer S, Rowe P, Lowe E, Hodgson D, Sovak MA, Matulonis U.
    Lancet Oncol; 2016 Nov 29; 17(11):1579-1589. PubMed ID: 27617661
    [Abstract] [Full Text] [Related]

  • 9. Development of Olaparib for BRCA-Deficient Recurrent Epithelial Ovarian Cancer.
    Tewari KS, Eskander RN, Monk BJ.
    Clin Cancer Res; 2015 Sep 01; 21(17):3829-35. PubMed ID: 26169965
    [Abstract] [Full Text] [Related]

  • 10. Olaparib maintenance monotherapy in platinum-sensitive, relapsed ovarian cancer without germline BRCA mutations: OPINION Phase IIIb study design.
    Poveda AM, Davidson R, Blakeley C, Milner A.
    Future Oncol; 2019 Nov 01; 15(32):3651-3663. PubMed ID: 31553234
    [Abstract] [Full Text] [Related]

  • 11. Talazoparib for BRCA-mutated advanced breast cancer.
    Gunjur A.
    Lancet Oncol; 2018 Oct 01; 19(10):e511. PubMed ID: 30146245
    [No Abstract] [Full Text] [Related]

  • 12. Movement of Poly-ADP Ribose (PARP) Inhibition into Frontline Treatment of Ovarian Cancer.
    Onstad M, Coleman RL, Westin SN.
    Drugs; 2020 Oct 01; 80(15):1525-1535. PubMed ID: 32852746
    [Abstract] [Full Text] [Related]

  • 13. BRCA1/2 testing: therapeutic implications for breast cancer management.
    Tung NM, Garber JE.
    Br J Cancer; 2018 Jul 01; 119(2):141-152. PubMed ID: 29867226
    [Abstract] [Full Text] [Related]

  • 14. Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer.
    Secord AA, Barnett JC, Ledermann JA, Peterson BL, Myers ER, Havrilesky LJ.
    Int J Gynecol Cancer; 2013 Jun 01; 23(5):846-52. PubMed ID: 23666017
    [Abstract] [Full Text] [Related]

  • 15. Olaparib for the treatment of BRCA-mutated advanced ovarian cancer.
    Munroe M, Kolesar J.
    Am J Health Syst Pharm; 2016 Jul 15; 73(14):1037-41. PubMed ID: 27385701
    [Abstract] [Full Text] [Related]

  • 16. PARP inhibitor receives FDA breakthrough therapy designation in castration resistant prostate cancer: beyond germline BRCA mutations.
    Helleday T.
    Ann Oncol; 2016 May 15; 27(5):755-7. PubMed ID: 26865580
    [No Abstract] [Full Text] [Related]

  • 17. FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy.
    Kim G, Ison G, McKee AE, Zhang H, Tang S, Gwise T, Sridhara R, Lee E, Tzou A, Philip R, Chiu HJ, Ricks TK, Palmby T, Russell AM, Ladouceur G, Pfuma E, Li H, Zhao L, Liu Q, Venugopal R, Ibrahim A, Pazdur R.
    Clin Cancer Res; 2015 Oct 01; 21(19):4257-61. PubMed ID: 26187614
    [Abstract] [Full Text] [Related]

  • 18. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
    Parkes EE, Kennedy RD.
    Oncologist; 2016 May 01; 21(5):586-93. PubMed ID: 27022037
    [Abstract] [Full Text] [Related]

  • 19. Olaparib Keeps Hereditary Breast Tumors in Check.
    Cancer Discov; 2017 Aug 01; 7(8):OF10. PubMed ID: 28583909
    [Abstract] [Full Text] [Related]

  • 20. Olaparib: first global approval.
    Deeks ED.
    Drugs; 2015 Feb 01; 75(2):231-40. PubMed ID: 25616434
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.